最高涨69%！北交所主题基金领跑前五月业绩榜单，多只医药基金净值创新高

Core Insights - The performance of actively managed equity funds in the first five months of 2025 shows a significant disparity, with the best-performing fund achieving a return of 69.30% and the worst losing over 37%, resulting in a nearly 108% difference between the top and bottom performers [1] - The average return for all 4,516 actively managed equity funds was 2.64%, with 190 funds exceeding a 20% return in the first two months [1] - The North Exchange 50 Index outperformed other indices, leading to strong performances from several North Exchange-themed funds and a rebound in pharmaceutical-themed funds due to the strong performance of the innovative drug sector [1] Fund Performance - The top two funds in terms of performance for the first five months of 2025 were the CITIC Securities North Exchange Selected Two-Year Open A, managed by Leng Wenpeng, with a return of 69.30%, and the Huaxia North Exchange Innovative Small and Medium Enterprises Selected Two-Year Open, managed by Gu Xinfeng, with a return of 67.38% [1][5] - Other notable funds include Changcheng Pharmaceutical Industry Selected A and Guangfa Growth Navigation One-Year Holding A, both exceeding 60% returns [3] Sector Analysis - The innovative drug sector has seen a significant increase in market costs since 2022, with a notable second wave of cost increases occurring after the Lunar New Year [4] - The analysis suggests that the second wave of cost increases in the innovative drug sector may present greater potential for returns compared to the first wave, driven by a combination of policy, capital, and industry dynamics [4]